Search

Displaying results 3051 - 3060 of 7186 in total
  1. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.

  2. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia … secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to

  3. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    The vaccine contains *N. meningitis* serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from *Corynebacterium … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  4. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456]. … The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001].

    International brands: NZ-105
  5. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    occurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the … plasma to act again.

  6. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available … classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.

  7. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.

  8. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

    Categories: Agents to Treat Airway Disease
  9. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

  10. Drug

    Ascorbyl phosphate

    go.drugbank.com/drugs/DB11352
    ApprovedInvestigational

    These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211]. … As vitamin C is susceptible to breakdown of compound and discoloration in cosmetic formulations, ascorbyl phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin